All News
Examples from the world of dermatology on JAK inhibitor success stories.
Bruce storber.
#RNL2024
@RheumNow https://t.co/S01lEIqjbR
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dermatology colleagues are using JAKis with success for wide range of dermatological diseases.
Note the beauty of this slide with further elaboration on domain inhibition, cool stuff 🤓
Bruce Strober
#RNL2024
@RheumNow https://t.co/2yHHcOgTC8
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
I am jealous of the derms who have topical JAKi!
Dr. Strober flaunts all the different JAKi he has at his disposal to treat derm diseases #RNL2024 @rheumnow https://t.co/qdMWCSA5I1
TheDaoIndex KDAO2011 ( View Tweet)
Dr. B Strober emphasizes that #AtopicDermatitis is not just found in children. A large proportion of patients are over 50 years of age when they are diagnosed. #RNL2024 @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Dr. Strober's JAKi in dermatology takeaways!
- Consider this for AD
- Dose matters in terms of both efficacy and toxicity
- Consider combination tx
- Topical JAKi option for vitiligo, especially head and neck involvement (harder in hands and other areas)
#RNL2024 @RheumNow https://t.co/ZrPfpUF4Hz
Dr. Rachel Tate uptoTate ( View Tweet)
JAKi are being used in inflammatory skin disease other than psoriasis:
#HydradenitisSuppurativa, #alopecia, #AtopicDermatitis and #vitiligo
- Dr. B Strober #RNL2024 @rheumnow https://t.co/FzPyATPB93
TheDaoIndex KDAO2011 ( View Tweet)
Face and neck vitiligo also responds to topical ruxolitinib. Dr. Strober #RNL2024 @RheumNow https://t.co/6N6A3Yq7RE
Dr. Rachel Tate uptoTate ( View Tweet)
Impressive results for alopecia totalis with baricitinib – Dr. Bruce Strober #RNL2024 @rheumnow https://t.co/OA0tpdRum2
TheDaoIndex KDAO2011 ( View Tweet)
Clinical pearl! Consider topical ruxolitinib for your AD patients. Dr. Strober at #RNL2024 @RheumNow https://t.co/Sxwvn1lAXB
Dr. Rachel Tate uptoTate ( View Tweet)
Deucravacitinib takes longer to work for PsO compared to UPA, IL-17i or IL23i; it’s better than apremilast. Side effects w/TYK2i: acne, mild⬆️CK, but zoster & lipid issues aren't seen much, & no CV risk warnings; Dr. Strober doesn't follow labs w/TYK2i. #RNL2024 @rheumnow https://t.co/05jKqL4wdx
TheDaoIndex KDAO2011 ( View Tweet)
Clinical pearl from #RNL2024 @RheumNow
Palmoplantar psoriasis is a great time for first-line JAK inhibitor - Ben Strober, Yale dermatology
JAK for atopic dermatitis - extremely rapid responses https://t.co/hHYdGl51n2
Eric Dein ericdeinmd ( View Tweet)
#RNL2024 @RheumNow
Bruce Strober on JAK in skin diseases - diverse benefits:
- PsO
- Atopic dermatitis
- Alopecia areata
- Hidradenitis suppurativa
- Vitiligo
- Lichen planus any many others https://t.co/I9XHVbFpvQ
Eric Dein ericdeinmd ( View Tweet)
More evidence to support role of Tyk2 in management
of skin psoriasis.
Dr.April Armstrong
#RNL2024
@RheumNow https://t.co/9vuuhJMj36
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Nice summary of data as to why IL-17 or IL-23 are generally favoured by dermatology for psoriasis @_AprilArmstrong @RheumNow #RNL2024 https://t.co/qfAn2AHilX
Richard Conway RichardPAConway ( View Tweet)
Dr. A. Armstrong's Key Takeaways for PsO.
TNFi - great in PsA and pregnancy
IL-17i - robust PsO efficacy and in PsA
IL-23i - robust in PsO, fewer injections, and efficacious in PsA.
#RNL2024 @RheumNow @_AprilArmstrong https://t.co/j8LaOGITuf
Dr. Rachel Tate uptoTate ( View Tweet)
Did you know of all the small oral molecules, #apremilast is the only one approved for all stages of #psoriasis (mild to severe)? - Dr. Armstrong polls the audience on their thoughts then revealing the correct answer #RNL2024 @rheumnow https://t.co/NXSiaaGp3p
TheDaoIndex KDAO2011 ( View Tweet)
Dr. A. Armstrong shares dermatology/dermatologist trends in PsO.
1. They tend to shorted then interval between injections as opposed to the amount of medication per dose.
2. Derms generally wait 6 months to switch meds
3. Like rheums, derms tend to switch classes (of tx agent)… https://t.co/HWbJMwnwkE https://t.co/bgKw7ynANN
Dr. Rachel Tate uptoTate ( View Tweet)
Dr. A. Armstrong shares dermatology/dermatologist trends in PsO.
1. They tend to shorted then interval between injections as opposed to the amount of medication per dose.
2. Derms generally wait 6 months to switch meds
3. Like rheums, derms tend to switch classes (of tx agent)… https://t.co/HWbJMwnwkE https://t.co/bgKw7ynANN
Dr. Rachel Tate uptoTate ( View Tweet)
When it comes to skin, this is how derms think and there is data to support this. - Dr. Amstrong on how IL-17i and IL23i are preferred over TNFi #psoriasis #RNL2024 @rheumnow https://t.co/UZWNgOljRh
TheDaoIndex KDAO2011 ( View Tweet)
Dermatologic approach to choosing treatment in psoriatic disease. The presence of psoriatic arthritis is an initial branch point and why co-management is so crucial in these patients @_AprilArmstrong @RheumNow #RNL2024 https://t.co/m26WiEUmPI
Richard Conway RichardPAConway ( View Tweet)